Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay Registry

Junfen Zhang, Celeste M Boesjes, Laura Loman, Esmé Kamphuis, Margreet L E Romeijn, Lotte S Spekhorst, Inge Haeck, Lian F van der Gang, Coco C Dekkers, Lisa P van der Rijst, Albert J Oosting, Paula van Lumig, Anneke M T van Lynden-van Nes, Ron A Tupker, Annieke Nijssen, Annebeth Flinterman, Klaziena Politiek, Wouter R H Touwslager, Wianda A Christoffers, Shiarra M StewartMarijke Kamsteeg, Marlies de Graaf, Marjolein S de Bruin-Weller, Marie-Louise A Schuttelaar*

*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Fingerprint

Dive into the research topics of 'Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay Registry'. Together they form a unique fingerprint.

Medicine & Life Sciences